Edit

TearScience

http://tearscience.com/en/

Last activity: 18.07.2021

Active

Categories: CareCauseDiagnosticsHardware

Headquartered in Morrisville, North Carolina, TearScience has pioneered diagnostic and treatment devices for evaporative dry eye, providing significant clinical improvement. Of the more than 100 million dry eye sufferers worldwide, approximately 70 percent have evaporative dry eye caused by lipid deficiency of the eye’s natural tear film. TearScience’s integrated, in-office system is the first to enable eye care professionals to address the root cause of evaporative dry eye.

Mentions

Location: United States, North Carolina, Morrisville

Employees: 51-200

Total raised: $129.5M

Founded date: 2005

Investors 3

Date	Name	Website
14.05.2021	EW Healthc...	ewhealthca...
-	Quaker Par...	quakerpart...
18.07.2021	General Ca...	generalcat...

Funding Rounds 3

Date	Series	Amount	Investors
26.02.2013	-	$70M	-
03.10.2011	-	$15M	-
05.05.2010	-	$44.5M	-

Mentions in press and media 23

Date	Title	Description
08.04.2016	TearScience Completes Series D Funding	TearScience, a Morrisville, N.C.-based medical device company, completed its Series D funding. The name of the backers and amount of the deal were not disclosed. Led by Joseph Boorady, President and CEO, TearScience is a medical device comp...
27.02.2013	4 life sciences CEOs on lessons learned the hard way	Tim Willis, president, CEO and co-founder, TearScience: “We were out raising a series C, and we thought we had done our due diligence on the firms we were working with, and we assumed incorrectly that they had money to (do deals). I had fou...
26.02.2013	TearScience Secured up to $70M in Funding from HealthCare Royalty Partners	TearScience, Inc., a Morrisville, North Carolina-based medical device company that focuses on the worldwide dry eye market, secured up to $70m in funding from HealthCare Royalty Partners. The company intends to use the capital to implement ...
26.02.2013	TearScience Secures Up to $70M	MORRISVILLE, NC, Privately held medical device company, today announced that it has secured up to $70 million in funding from HealthCare Royalty Partners. >> Click here for more funding data on TearScience >> To export TearS...
17.05.2012	MAKO’s plunge may be good news for buyers \| Wall Street Beat	Mako Surgical (NSDQ:MAKO) has had a tough month on Wall Street, with shares having lost 45% since the end of April, but not everyone is running for the hills. Earlier this week a company director, Frederick Moll, picked up another 5,000 sha...
16.05.2012	New CFO for TearScience as the device firm weighs acquisition, IPO plans	The LipiFlow technology initially received U.S. Food and Drug Administration 510(k) clearance last year. Software and a hand-held unit that doctors use with the device received 510(k) clearance in February. The complete system unit is now b...
15.02.2012	Pharmas, medical device makers set to pitch at CED Life Science conference	A total of 16 companies are scheduled to make presentations, split evenly between pharmaceuticals and medical devices. Here’s a quick rundown of the presenting companies, all of whom are either based in North Carolina’s Research Triangle or...
07.02.2012	How TearScience’s dry eye treatment sparked a new FDA 510(k) strategy	“If you tried to do both of these filings (at once), especially in this regulatory environment, I doubt we’d get cleared by now,” he said. An estimated 100 million people worldwide have dry eyes, many of them suffering from evaporative dry ...
01.02.2012	Dry eye treatment from TearScience gets FDA 510(k) clearance	Privately held TearScience, founded in 2005, has raised more than $70 million in venture capital financing from Essex Woodlands Health Ventures, Investor Growth Capital, General Catalyst, De Novo Ventures, Spray Ventures and Quaker Partners...
03.10.2011	TearScience lands $15M to bring novel dry eye treatment to market	An estimated 100 million people worldwide suffer from dry eyes. While dry eyes can be caused by the failure of the eye to produce enough tears, TearScience’s technology targets the 65 percent who have evaporative dry eye, a condition in whi...
16.08.2011	Allergan veteran to lead TearScience European business	Between 20 million and 30 million Americans suffer from dry eyes, according to market research from CBDM.T. The firm projects that the dry eye market will reach $2.4 billion by 2014. But dry eye products on the market consist mainly of drug...
16.07.2011	Cleveland Clinic hotel gets ‘well’ (Weekend Rounds)	Cleveland Clinic, Chris Coburn’s big payoff (and challenge): $840,000. Obviously the Clinic wants to reward star performers like Coburn for the financial gain they’ve helped bring to the health system. But it’s not a stretch to think that i...
11.07.2011	Medical device dry-eye treatment LipiFlow wins FDA approval	Approximately 30 million to 40 million people in the United States deal with dry eye disease, and it is one of the most common reasons people see an eye doctor, according to CBDM.T’s 2010 report on the dry eye market. CBDM.T estimated the d...
05.05.2010	TearScience Completes $44.5M Financing Round	TearScience, a Morrisville, North Carolina-based medical device company, completed a $44.5m Series C funding. The round includes new investors Essex Woodlands Health Ventures, Investor Growth Capital and General Catalyst, as well as existin...
-	Dry eye treatment from TearScience gets FDA 510(k) clearance	Medical device company TearScience has received 510(k) clearance on the latest version of its evaporative dry eye treatment. The Morrisville, North Carolina company’s novel dry eye treatment initially received U.S. Food and Drug Administrat...
-	New CFO for TearScience as the device firm weighs acquisition, IPO plans	Dry eye treatment company TearScience, which is considering plans for an initial public stock offering, now has a new chief financial officer. The medical device company has promoted Nicole Wicker from vice president of finance to CFO. Wick...
-	Pharmas, medical device makers set to pitch at CED Life Science conference	Life science companies and investors, let’s make a deal. The annual CED Life Science Conference kicks off in Raleigh, North Carolina today where small drug developers hope to make the right connection with a big pharmaceutical company or ve...
-	Medical device dry-eye treatment LipiFlow wins FDA approval	A medical device dry-eye treatment that wants to replace eye drops has received U.S. Food and Drug Administration approval. North Carolina’s TearScience has won FDA approval for its LipiFlow Thermal Pulsation device, which can eliminate gla...
-	TearScience lands $15M to bring novel dry eye treatment to market	Medical device company TearScience has secured $15 million in debt financing that the company will use to support a pair of products addressing evaporative dry eye. The venture debt financing comes from Oxford Finance and Silicon Valley Ban...
-	How TearScience’s dry eye treatment sparked a new FDA 510(k) strategy	The dry eye treatment developed by TearScience received 510(k) clearance last week, about seven months after the company’s novel medical device received its first marketing go-ahead from the U.S. Food and Drug Administration. While the spee...
-	Allergan veteran to lead TearScience European business	Medical device company TearScience has hired a former Allergan (NYSE:AGN) executive to spearhead European commercialization efforts for its novel dry eye treatment. Deithart Reichardt is now senior vice president of the European region for ...
-	Cleveland Clinic hotel gets ‘well’ (Weekend Rounds)	A review of life science current events reported by MedCity News this week: Cleveland Clinic hotel on main campus undergoes ‘wellness’ renovation. The InterContinental Suites Hotel’s nine-month-long renovation project is scheduled to wrap u...
-	4 life sciences CEOs on lessons learned the hard way	There are some lessons that no amount of reading can teach an entrepreneur. Sometimes, you just have to learn by doing. And that goes for companies at all stages, as a panel of CEOs at the CED Life Science Conference shared on Wednesday. Du...

TearScience

Investors 3

Funding Rounds 3

Mentions in press and media 23

Reviews 0